(1R,5S/1S,5R)-1-[4-(4-chloro-2-fluorophenyl)]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1R,5S/1S,5R)-1-[4-(4-chloro-2-fluorophenyl)]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane
• 英文别名: 5-[5-[3-[(1R,5S)-1-(4-chloro-2-fluorophenyl)-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole
• 化学式: C₂₁H₂₃ClFN₅OS
• 分子量: 447.964
• InChiKey: MDHNTQJUKKBCMM-SPLOXXLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  85.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (1R,5S/1S,5R)-1-[4-(4-chloro-2-fluorophenyl)]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 、 水 为溶剂， 生成 (1R,5S/1S,5R)-1-[4-(4-chloro-2-fluorophenyl)]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
  参考文献：
  名称：

  1,2,4-三唑基氮杂双环[3.1.0]己烷：一系列新的有效和选择性的多巴胺D 3受体拮抗剂

  摘要：

  最近发现了新的强效和选择性多巴胺（DA）D 3受体拮抗剂，这种药物可以在一系列成瘾的临床前动物模型中表征DA D 3受体。本文报道了一系列新的1,2,4-三唑-3-基-氮杂双环[3.1.0]己烷，其成员对DA D 3受体显示出高亲和力和选择性，并具有出色的药代动力学特征。该系列衍生物的成员显示出良好的口服生物利用度和脑渗透性，并且对DA D 3的体外亲和力和选择性非常高受体，以及在该受体上具有高的体外拮抗作用。该系列的几个成员还显着减弱了条件位置偏爱（CPP）对尼古丁和可卡因的表达。

  DOI：

  10.1021/jm901319p
• 作为产物：
  描述：

  3-[(3-氯丙基)硫基]-4-甲基-5-(4-甲基-1,3-恶唑-5-基)-4H-1,2,4-三唑 、 (1R,5S/1S,5R)-1-(4-chloro-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane 在 potassium carbonate 作用下， 生成 (1R,5S/1S,5R)-1-[4-(4-chloro-2-fluorophenyl)]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane
  参考文献：
  名称：

  1,2,4-三唑基氮杂双环[3.1.0]己烷：一系列新的有效和选择性的多巴胺D 3受体拮抗剂

  摘要：

  最近发现了新的强效和选择性多巴胺（DA）D 3受体拮抗剂，这种药物可以在一系列成瘾的临床前动物模型中表征DA D 3受体。本文报道了一系列新的1,2,4-三唑-3-基-氮杂双环[3.1.0]己烷，其成员对DA D 3受体显示出高亲和力和选择性，并具有出色的药代动力学特征。该系列衍生物的成员显示出良好的口服生物利用度和脑渗透性，并且对DA D 3的体外亲和力和选择性非常高受体，以及在该受体上具有高的体外拮抗作用。该系列的几个成员还显着减弱了条件位置偏爱（CPP）对尼古丁和可卡因的表达。

  DOI：

  10.1021/jm901319p

文献信息

• Use of Azabicyclo Hexane Derivatives
  申请人：Hamprecht Dieter

  公开号：US20090036461A1

  公开（公告）日：2009-02-05

  The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl; R 3 I s C 1-4 alkyl; R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; R 5 is a moiety selected from the group consisting of: isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1, such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1; in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.

  本发明提供了化合物(I)或其药学上可接受的盐或溶剂盐的新用途：其中：G选择自苯基、吡啶基、苯并噻唑基、吲哚基的群组;p为0至5的整数；R1独立地选择自卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基；或对应于R5基团；R2为氢或C1-4烷基；R3为C1-4烷基；R4为氢、苯基、杂环基、5-或6-成员杂芳基、或8-至11-成员双环基中的任何一种，其中任何一种基团均可选地被1、2、3或4个来自卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4酰基的取代基所取代；R5为从异恶唑基、—CH2—N-吡咯基、1,1-二氧化-2-异噻唑烷基、噻唑基、吡啶基、2-吡咯烷酰基中选择的基团，并且此类基团可选地被1或2个来自卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4酰基的取代基所取代；当R1为氯且p为1时，此类R1不位于与分子其余部分的连接键的正交位置；当R1对应于R5时，p为1；用于制造治疗躯体形式障碍（如身体畸形障碍或健忘症）、暴食症、厌食症、暴饮暴食、性变态和非性变态性瘾症、辛德汉舞蹈病、斜颈、自闭症、包括图雷特综合症在内的运动障碍的药物；以及用于制造治疗早泄的药物。
• Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors
  申请人：Arista Luca

  公开号：US20070142438A1

  公开（公告）日：2007-06-21

  The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 1. wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, halo 1-4 alkoxy, C 1-4 alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl; R 3 is C 1-4 alkyl; R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; R 5 is a moiety selected from the group consisting of: isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, halo 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1, such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1; or a salt thereof which are useful as modulators of dopamine D 3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

  本发明涉及公式（I）的新化合物或其药学上可接受的盐：1.其中G选自以下组中的一组：苯基，吡啶基，苯并噻唑基，吲哚基；p为0至5的整数；R1独立地选自以下组中的一组：卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代1-4烷氧基，C1-4酰基；或对应于R5基团；R2为氢或C1-4烷基；R3为C1-4烷基；R4为氢，苯基，杂环基，5-或6-成员杂芳基，或8-至11-成员双环基中的一种，其中任何一种基团均可选择性地被1、2、3或4个来自以下组的取代基所取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4酰基；R5是从以下组中选择的一部分：异噁唑基，-CH2-N-吡咯基，1,1-二氧化-2-异硫氮基，噻唑基，噻唑基，吡啶基，2-吡咯烷基，这样的基团可以选择地被一个或两个取代基所取代：卤素，氰基，C1-4烷基，卤代1-4烷基，C1-4烷氧基，C1-4酰基；当R1为氯且p为1时，该R1不位于与分子的其余部分的连接键的邻位上；当R1对应于R5时，p为1；或其盐，它们可用作多巴胺D3受体的调节剂，例如用于治疗药物依赖或作为抗精神病药物。
• Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors
  申请人：Arista Luca

  公开号：US20100152195A1

  公开（公告）日：2010-06-17

  The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl; R 3 is C 1-4 alkyl; R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; R 5 is a moiety selected from the group consisting of: isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1, such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

  本发明涉及公式（I）的新化合物或其药学上可接受的盐： 其中， G选自以下组：苯基，吡啶基，苯并噻唑基，吲唑基； p为0至5的整数； R1独立地选自以下组：卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4酰基；或对应于R5的基团； R2为氢或C1-4烷基； R3为C1-4烷基； R4为氢，苯基，杂环基，5-或6-成员杂芳基，或8-到11-成员双环基中的任何一种，其中任何一种基团均可选择地被1、2、3或4个取代基所取代，所述取代基选自以下组：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4酰基； R5为以下组中选择的基团：异恶唑基，—CH2—N-吡咯基，1，1-二氧化-2-异噻唑烷基，噻唑基，噻唑基，吡啶基，2-吡咯烷酮基，所述基团可选择地被1或2个取代基所取代，所述取代基选自以下组：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4酰基； 当R1为氯且p为1时，该R1不位于与分子其余部分的连接键的邻位；当R1对应于R5时，p为1； 本发明还涉及制备这些化合物的方法，用于这些方法的中间体，包含它们的制药组合物以及它们作为多巴胺D3受体调节剂的用途，例如用于治疗药物依赖或作为抗精神病药物。
• USE OF AZABICYCLO HEXANE DERIVATIVES
  申请人：HAMPRECHT Dieter

  公开号：US20120196910A1

  公开（公告）日：2012-08-02

  The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome.

  本发明提供了化合物(I)或其药学上可接受的盐或溶剂盐的一种新用途：用于治疗躯体形式障碍，如身体畸形障碍或疑病症，暴食症，厌食症，暴食症，性偏执症和非性偏执性性成瘾，辛德汉舞蹈症，斜颈，自闭症，包括图雷特综合征在内的运动障碍。
• US7855298B2
  申请人：——

  公开号：US7855298B2

  公开（公告）日：2010-12-21